Data mart

Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research at 2024 MDA Clinical & Scientific Conference

Retrieved on: 
Friday, March 1, 2024
Real-World Evidence, Massachusetts General Hospital, Spirometry, Data mart, ALS, Doctor of Philosophy, Interim analysis, Edaravone, M.S, Hospital, Conference, Natural history, State university system, Abstract, CDM, SVC, MDA, Phase 4, Episcopal conference, MTPA, Pharmaceutical industry

JERSEY CITY, N.J., March 1, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.

Key Points: 
  • JERSEY CITY, N.J., March 1, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.
  • "These presentations reinforce our commitment to making a positive impact on the ALS community by better understanding disease markers and outcomes and providing important information on our treatment options for clinical practice."
  • Interim Analysis of the Radicava/Edaravone Findings in Biomarkers from ALS (REFINE-ALS) Study (James Berry, M.D., M.P.H.
  • Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients With Amyotrophic Lateral Sclerosis (Dung Pham, PhD; MTPA-CA)

Mitsubishi Tanabe Pharma America Announces Presentations in ALS at 34th International Symposium on ALS/MND

Retrieved on: 
Tuesday, December 5, 2023
Data mart, SVC, Research, Safety, ALS, MGH, State university system, Motor Neurone Disease Association, Spirometry, Disease, CET, MTPA, Part, MNDA, Medical Affairs Bureau, Abstract, CDM, Edaravone, Massachusetts General Hospital, NCRI, Hospital, Pharmaceutical industry, Communications satellite, Telehealth, Biomarker, Patient, Optum

JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.

Key Points: 
  • JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.
  • MTPA's posters will be displayed during poster sessions held in the Event Halle on December 6 and 7.
  • A Preliminary Analysis of Oral Edaravone-Treated Patients with Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database (Malgorzata Ciepielewska, M.S.
  • ; State University of New York Upstate Medical University)
    Poster Session B (Part 1), 5:45 p.m. – 6:45 p.m. CET, Dec. 7

Mitsubishi Tanabe Pharma America Spotlights ALS Research at the XXVI World Congress of Neurology

Retrieved on: 
Monday, October 16, 2023
Congress, ALS, FRCP, MBA, McGill University Health Centre, Abstract, Edaravone, MHA, Safety, Sunnybrook Health Sciences Centre, Hospital, IV, Database, MTPA, Data mart, EDT, Virtual machine, XXVI, WCN, CDM, Research, Pharmaceutical industry, Neurology, Optum, Patient

JERSEY CITY, N.J., Oct. 16, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the XXVI World Congress of Neurology (WCN), being held virtually and in-person in Montreal, Quebec, October 15-19.

Key Points: 
  • JERSEY CITY, N.J., Oct. 16, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the XXVI World Congress of Neurology (WCN), being held virtually and in-person in Montreal, Quebec, October 15-19.
  • "These presentations reflect the importance of combining insights from clinical and real-world settings to better understand the potential of our current treatment options and their impact on ALS."
  • MTPA's posters will be viewable in the Virtual Platform and onsite throughout the conference.
  • Additionally, 48-week safety results from the global Phase 3 multi-center, open-label clinical trial ( MT-1186-A01 ) evaluating RADICAVA ORS in people with ALS will be presented.

Mitsubishi Tanabe Pharma America Showcases Depth of ALS Research with Wide Range of Abstracts at 22nd Annual NEALS Meeting

Retrieved on: 
Wednesday, October 4, 2023
Real-World Evidence, Medical Affairs Bureau, Mitsubishi Tanabe Pharma, MGH, IDMC, MND, ALS, Research, NCRI, Mitsubishi Group, Biomarker, Data mart, Intravenous therapy, MTPA, CDM, Netherlands Institute for Sound and Vision, NHC, Survival, University Challenge 2013–14, Hospital, Patient, SVC, FDA, Massachusetts General Hospital, Disease, Pharmaceutical industry, Nursing, Edaravone, Safety, Optum

JERSEY CITY, N.J., Oct. 4, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that eight presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held in Clearwater, Fla., from October 4-6.

Key Points: 
  • JERSEY CITY, N.J., Oct. 4, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that eight presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held in Clearwater, Fla., from October 4-6.
  • Presentations include:
    A preliminary analysis of demographics and clinical characteristics in people with ALS being treated with RADICAVA ORS, utilizing U.S.-based administrative claims data from Optum's Clinformatics® Data Mart (CDM), will be presented.
  • REFINE-ALS is a NEALS-affiliated clinical trial sponsored by MTPA and conducted in collaboration with the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH).
  • Real-World Survival Effectiveness of Edaravone in Amyotrophic Lateral Sclerosis: A Propensity Score Weighted, Registry-based, Canada-wide Cohort Study
    Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients With Amyotrophic Lateral Sclerosis

Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023

Retrieved on: 
Friday, August 25, 2023
Biotechnology, General Health, Health, Pharmaceutical, Cardiology, Ochsner Health System, Bleeding, Pfizer, Senior, Trial of the century, Stroke, FACP, PFE, FACC, RVT, NVAF, European Society of Cardiology, Bristol Myers Squibb, PSM, Medicine, Pharmacy, Data mart, Congress, Anticoagulant, Hospital medicine, MMM, Patient, Risk, Causality, Rivaroxaban, Confidence interval, Clutch (eggs), BMS, ESC, Safety, Pharmaceutical industry, Medical imaging, Apixaban, MB, Ventricular fibrillation, ATHENS, MD

There were 167,868 Eliquis initiators and 65,888 rivaroxaban initiators who met study criteria.

Key Points: 
  • There were 167,868 Eliquis initiators and 65,888 rivaroxaban initiators who met study criteria.
  • It is important to note that anticoagulants, including Eliquis, increase the risk of bleeding and can cause serious, potentially fatal bleeding.
  • Additionally, reasons for switching are not known and sample size for those who switched is much lower than those who continued treatment.
  • Due to these limitations, real-world data analyses are not used as evidence to validate the efficacy and/or safety of a treatment.

Optum Applauded by Frost & Sullivan for Advancing the Use of Real-World Evidence by Life Sciences Companies and for Its Market-leading Position

Retrieved on: 
Wednesday, August 23, 2023
Automotive Executive of the Year Award, Information technology, Medicine, Research, RWD, Electronic health record, Data mart, Frost, North American Company, Patient, EHR, Investment, SAN, RWE, Optum, The Wheel of Time, Epidemiology, Health information management, Management, Nursing

SAN ANTONIO, Aug. 23, 2023 /PRNewswire/ -- Frost & Sullivan recently assessed the landscape for real-world evidence (RWE) information technology (IT) solutions for the healthcare industry and, based on its research results, recognizes Optum with the 2023 North American Company of the Year Award. The RWE division operates in the healthcare life sciences industry, with access to 285 million lives worth of deidentified real-world data (RWD). The division of Optum focused on RWE IT solutions specializes in real-world data, health economics and outcomes research (HEOR), epidemiology, and commercial analytics. The company has worked with RWE for over 25 years and offers a long-term perspective to maintain sustainability, thus providing information to regulators, providers, payers, and patients. The company aims to make healthcare simpler and more effective by transforming evidence into action.

Key Points: 
  • The RWE division operates in the healthcare life sciences industry, with access to 285 million lives worth of deidentified real-world data (RWD).
  • The division of Optum focused on RWE IT solutions specializes in real-world data, health economics and outcomes research (HEOR), epidemiology, and commercial analytics.
  • Ojaswi Rana, Best Practices Research Analyst, Frost & Sullivan, added, "Optum's research-ready RWD fuels RWE, distinguishing it from other market participants.
  • Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

Optum Applauded by Frost & Sullivan for Advancing the Use of Real-World Evidence by Life Sciences Companies and for Its Market-leading Position

Retrieved on: 
Wednesday, August 23, 2023
Automotive Executive of the Year Award, Information technology, Medicine, Research, RWD, Electronic health record, Data mart, Frost, North American Company, Patient, EHR, Investment, SAN, RWE, Optum, The Wheel of Time, Epidemiology, Health information management, Management, Nursing

SAN ANTONIO, Aug. 23, 2023 /PRNewswire/ -- Frost & Sullivan recently assessed the landscape for real-world evidence (RWE) information technology (IT) solutions for the healthcare industry and, based on its research results, recognizes Optum with the 2023 North American Company of the Year Award. The RWE division operates in the healthcare life sciences industry, with access to 285 million lives worth of deidentified real-world data (RWD). The division of Optum focused on RWE IT solutions specializes in real-world data, health economics and outcomes research (HEOR), epidemiology, and commercial analytics. The company has worked with RWE for over 25 years and offers a long-term perspective to maintain sustainability, thus providing information to regulators, providers, payers, and patients. The company aims to make healthcare simpler and more effective by transforming evidence into action.

Key Points: 
  • The RWE division operates in the healthcare life sciences industry, with access to 285 million lives worth of deidentified real-world data (RWD).
  • The division of Optum focused on RWE IT solutions specializes in real-world data, health economics and outcomes research (HEOR), epidemiology, and commercial analytics.
  • Ojaswi Rana, Best Practices Research Analyst, Frost & Sullivan, added, "Optum's research-ready RWD fuels RWE, distinguishing it from other market participants.
  • Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

Pricefx Brings Advanced Capabilities to its Award-Winning Pricing Platform

Retrieved on: 
Tuesday, June 27, 2023
Software, Technology, Artificial Intelligence, Integration, Paper plane, Data mart, API, SAP, Paper, CRM, AI, Video game, Sales, Retail

Pricefx , the global leader in cloud-native pricing software, today announced it has released the Paper Plane 11.0 version of its pricing platform.

Key Points: 
  • Pricefx , the global leader in cloud-native pricing software, today announced it has released the Paper Plane 11.0 version of its pricing platform.
  • With actionable insights capabilities, businesses can continuously identify gaps and opportunities with smart data-driven automation, and then choose the optimal course of action.
  • In response, we’ve improved our pricing platform to deliver more value to customers, faster,” said Billy Graham, Chief Product Officer for Pricefx.
  • Pricefx’s Visual Configuration adds simplified configuration options across various functionalities and extends the capabilities of Pricefx Accelerators.

Mitsubishi Tanabe Pharma America to Present Latest Findings Across ALS and Parkinson's Disease at 2023 American Academy of Neurology Annual Meeting

Retrieved on: 
Thursday, April 20, 2023
Mitsubishi Tanabe Pharma, Medical Affairs Bureau, PD, Edaravone, IV, Disease, Phase II, AAN, Safety, Rush University Medical Center, Efficacy, ALS, American Academy, Research, Plenary session, EDT, Data mart, Beyond, DSM-IV codes, MTPA, Parkinson's disease, CDM, Randomness, Annual general meeting, Oral, L-DOPA, Carbidopa/levodopa, FAAN, American Academy of Neurology, Pharmaceutical industry, Medicinal plants, Communications satellite, Boundless, Optum, Patient

JERSEY CITY, N.J., April 20, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced six presentations in amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD) will be shared as part of the 2023 American Academy of Neurology (AAN) Annual Meeting, being held virtually and in Boston, Mass., April 22-27.

Key Points: 
  • JERSEY CITY, N.J., April 20, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced six presentations in amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD) will be shared as part of the 2023 American Academy of Neurology (AAN) Annual Meeting, being held virtually and in Boston, Mass., April 22-27.
  • The latter will be presented orally as part of a Scientific Platform Session at the meeting.
  • All three studies are being conducted by NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), MTPA's parent company.
  • Efficacy and Safety of Continuous Subcutaneous ND0612 Infusion Compared with Oral Immediate-release Levodopa-Carbidopa in Patients with Parkinson's Disease and Motor Fluctuations.

Mitsubishi Tanabe Pharma America Announces Presentations in ALS at 2023 MDA Clinical & Scientific Conference

Retrieved on: 
Friday, March 17, 2023
Database, Medical Affairs Bureau, IV, National Primate Research Exhibition Hall, Edaravone, Safety, ALS, Research, Mitsubishi Tanabe Pharma, Data mart, MTPA, CDM, Episcopal conference, Patient, MDA, Massachusetts General Hospital, Conference, Pharmaceutical industry, Optum, MPH

JERSEY CITY, N.J., March 17, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations on amyotrophic lateral sclerosis (ALS) as part of the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held virtually and in Dallas, Tex., March 19-22.

Key Points: 
  • JERSEY CITY, N.J., March 17, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations on amyotrophic lateral sclerosis (ALS) as part of the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held virtually and in Dallas, Tex., March 19-22.
  • "These presentations reflect our determination to not only broaden our expertise in ALS, but to continue sharing key insights that have a meaningful impact on the patient and medical communities."
  • MTPA's posters will be viewable in-person and virtually during the conference, as well as showcased in the Exhibit Halls from 6:00-8:00 p.m. CT.
  • The ongoing study is sponsored by Mitsubishi Tanabe Pharma Development America, Inc. (MTDA).